Medical Terminology


« Back to Glossary Index

Selegiline (Emsam, Eldepryl, Zelapar) is in a group of medications called monoamine oxidase type B (MAO-B) inhibitors, which means that it works by slowing the breakdown of certain substances in the brain (mostly dopamine). Selegiline was approved by the U.S. FDA in 1989 for the treatment of Parkinson’s disease, to help control the difficulties with movement, muscle control and balance. Even though selegiline has been reported to decrease excessive daytime sleepiness, it is usually not prescribed for narcolepsy because of the high dosage required. Read more about selegiline at HERE and on HF’s Treatment web page HERE.

Emsam, Eldepryl, Zelapar

The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.